WeVote
Log In

Bill

Bill

SF 3822

Use of prior authorization and step therapy prohibition for drugs used in the treatment of opioid use disorder under medical assistance

2025-2026 Regular Session Introduced by Omar Fateh

Minnesota bill removes prior authorization and step therapy barriers for opioid use disorder medications in Medicaid to improve treatment access.

Referred to Health and Human Services
#drugsandmedicine #humanservicesandhumanservicesdepartment
0
WeVote Research Nonpartisan
Bill Summary · SF 3822

Legislative bill overview

SF 3822 prohibits prior authorization and step therapy requirements for medications used to treat opioid use disorder (OUD) under Minnesota's medical assistance programs. Prior authorization requires doctors to get insurer approval before prescribing, while step therapy mandates patients try cheaper drugs first. The bill would eliminate these administrative barriers specifically for OUD treatments like methadone, buprenorphine, and naltrexone.

Why is this important

Opioid use disorder is a serious public health crisis, and medication-assisted treatment (MAT) is evidence-based care that reduces overdose deaths and improves outcomes. Administrative delays from prior authorization can cause patients to abandon treatment, increase overdose risk, and worsen health outcomes. Removing these barriers could make life-saving medications more immediately accessible to vulnerable populations on medical assistance.

Potential points of contention

  • Cost concerns: Insurers and policymakers may worry about increased prescription costs without prior authorization controls, though research suggests MAT reduces overall healthcare spending through fewer emergency services and hospitalizations
  • Scope definition: Unclear whether "drugs used in treatment of OUD" covers only FDA-approved MAT medications or broader supportive pharmaceuticals, which could affect implementation costs
  • Program applicability: The bill specifically targets medical assistance (Medicaid), not private insurance, raising equity questions about whether privately insured patients should have different access standards

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.